Official Title
Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population
Brief Summary

CORONAVIT is an open-label, phase 3, randomised clinical trial testing whether implementation of a test-and-treat approach to correction of sub-optimal vitamin D status results in reduced risk and/or severity of COVID-19 and other acute respiratory infections.

Status
Completed
Conditions
COVID19
Acute Respiratory Tract Infection
Interventions

Dietary Supplement: Vitamin D

Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Eligibility Criteria

Inclusion criteria:

1. UK resident

2. Age ≥16 years

3. Gives informed consent to participate

Exclusion criteria:

1. taking digoxin, alfacalcidol, calcitriol, dihydrotachysterol or paricalcitol

2. known diagnosis of sarcoidosis, primary hyperparathyroidism, renal stones or renal
failure requiring dialysis

3. known allergy to any ingredient in the study capsules (vitamin D, olive oil, caramel,
gelatine or glycerol)

4. pregnancy

Eligibility Gender
All
Eligibility Age
Minimum: 16 Years ~ Maximum: N/A
Countries
United Kingdom
Locations

Queen Mary University of London
London, County (optional), United Kingdom

Sponsors / Collaborators
Queen Mary University of London
NCT Number
NCT04579640
MeSH Terms
Infections
Communicable Diseases
COVID-19
Respiratory Tract Infections
Vitamin D